ECSP23077322A - Derivados de fósforo como nuevos inhibidores de sos1 - Google Patents

Derivados de fósforo como nuevos inhibidores de sos1

Info

Publication number
ECSP23077322A
ECSP23077322A ECSENADI202377322A ECDI202377322A ECSP23077322A EC SP23077322 A ECSP23077322 A EC SP23077322A EC SENADI202377322 A ECSENADI202377322 A EC SENADI202377322A EC DI202377322 A ECDI202377322 A EC DI202377322A EC SP23077322 A ECSP23077322 A EC SP23077322A
Authority
EC
Ecuador
Prior art keywords
compounds
new
phosphorus derivatives
sos1
preparation
Prior art date
Application number
ECSENADI202377322A
Other languages
English (en)
Inventor
Jeremie Xavier G Mortier
Jens SCHRÖDER
Atanas Marinov Kamburov
Keith Graham
Gerhard Siemeister
Michael Erkelenz
Roman Hillig
Benjamin Bader
Timo Stellfeld
Christoph Philipp Hethey
Matthias Arlt
Felix Pape
Steffen Gressies
Katrin Nowak-Reppel
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of ECSP23077322A publication Critical patent/ECSP23077322A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6568—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms
    • C07F9/65685—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms the ring phosphorus atom being part of a phosphine oxide or thioxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención abarca los derivados de fósforo de la fórmula general (I): [IMAGEN ADJUNTA], en donde R1, R2, R3, R4, R5, R6, X1, X2, X3, X4 e Y son como se definen en el presente documento, métodos de preparación de dichos compuestos, compuestos intermedios útiles para la preparación de dichos compuestos, composiciones farmacéuticas y combinaciones que comprenden dichos compuestos y el uso de dichos compuestos para la fabricación de composiciones farmacéuticas para el tratamiento o profilaxis de enfermedades, en particular de trastornos hiperproliferativos, especialmente enfermedades asociadas a SOS1, como agente único o en combinación con otros ingredientes activos.
ECSENADI202377322A 2021-04-14 2023-10-12 Derivados de fósforo como nuevos inhibidores de sos1 ECSP23077322A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP21168256.2A EP4074317A1 (en) 2021-04-14 2021-04-14 Phosphorus derivatives as novel sos1 inhibitors

Publications (1)

Publication Number Publication Date
ECSP23077322A true ECSP23077322A (es) 2023-11-30

Family

ID=75529812

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202377322A ECSP23077322A (es) 2021-04-14 2023-10-12 Derivados de fósforo como nuevos inhibidores de sos1

Country Status (22)

Country Link
US (1) US20240247015A1 (es)
EP (2) EP4074317A1 (es)
JP (1) JP2024513595A (es)
KR (1) KR20230170032A (es)
CN (1) CN117500507A (es)
AR (1) AR125672A1 (es)
AU (1) AU2022258751A1 (es)
BR (1) BR112023019030A2 (es)
CA (1) CA3216503A1 (es)
CL (1) CL2023003045A1 (es)
CO (1) CO2023013469A2 (es)
CR (1) CR20230485A (es)
DO (1) DOP2023000218A (es)
EC (1) ECSP23077322A (es)
GE (1) GEAP202316387A (es)
IL (1) IL307448A (es)
JO (1) JOP20230252A1 (es)
MX (1) MX2023012187A (es)
PE (1) PE20240022A1 (es)
PH (1) PH12023552869A1 (es)
TW (1) TW202304467A (es)
WO (1) WO2022219035A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115461342B (zh) * 2020-05-09 2025-02-21 正大天晴药业集团股份有限公司 含磷的sos1抑制剂
US20230357239A1 (en) * 2020-09-18 2023-11-09 Bayer Aktiengesellschaft Pyrido[2,3-d]pyrimidin-4-amines as sos1 inhibitors
CN116425796A (zh) * 2022-01-12 2023-07-14 如东凌达生物医药科技有限公司 一类嘧啶并杂环类化合物、制备方法和用途
WO2024056782A1 (en) * 2022-09-16 2024-03-21 Bayer Aktiengesellschaft Sulfone-substituted pyrido[3,4-d]pyrimidine derivatives for the treatment of cancer
CR20250420A (es) 2023-04-07 2025-11-20 Revolution Medicines Inc Inhibidores macrocíclicos de ras
AR132338A1 (es) 2023-04-07 2025-06-18 Revolution Medicines Inc Inhibidores de ras
CN121464140A (zh) 2023-04-14 2026-02-03 锐新医药公司 Ras抑制剂的结晶形式、含有其的组合物及其使用方法
CN121100123A (zh) 2023-04-14 2025-12-09 锐新医药公司 Ras抑制剂的结晶形式
WO2026032865A1 (en) 2024-08-09 2026-02-12 Bayer Aktiengesellschaft Salt of a sos-1 inhibitor

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2015A (en) 1841-03-26 Improvement in rotary steam-engines
IL89027A (en) 1988-01-29 1993-01-31 Lilly Co Eli Quinazoline derivatives, process for their preparation and fungicidal, insecticidal and miticidal compositions containing them
IL89028A0 (en) 1988-01-29 1989-08-15 Lilly Co Eli Quinoline,quinazoline and cinnoline derivatives
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
US5236925A (en) 1991-10-24 1993-08-17 American Home Products Corporation Fused pyrimidines as angiotensin II antagonists
WO1999010330A1 (en) 1997-08-25 1999-03-04 Bayer Corporation Heterocyclic ketones as npy y5 antagonists
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US7238679B2 (en) * 2002-12-23 2007-07-03 Ariad Pharmaceuticals, Inc. Heterocycles and uses thereof
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
WO2005005382A2 (en) 2003-07-02 2005-01-20 Cytokinetics, Inc. Compounds, compositions and methods
DE602004004278T2 (de) 2003-08-15 2007-10-31 Merck & Co, Inc. 4-cycloalkylaminopyrazolopyrimidin als nmda/nr2b-antagonisten
ZA200609259B (en) 2004-04-30 2008-07-30 Takeda Pharmaceutical Heterocyclic amide compound and use thereof as an mmp-13 inhibitor
SE0401540D0 (sv) 2004-06-15 2004-06-15 Astrazeneca Ab New compounds
ITMI20042042A1 (it) 2004-10-26 2005-01-26 Pharmeste Srl Derivati solfonammidici antagonisti del recettore dei vanilloidi trpv1
ES2569881T3 (es) 2005-06-08 2016-05-12 The University Of North Carolina At Chapel Hill Procedimientos para facilitar la supervivencia de células neuronales usando miméticos de neurotrofina BDNF peptídicos y no peptídicos
MX2008014689A (es) 2006-05-23 2008-11-27 Hoffmann La Roche Derivados de piridopirimidininona.
CA2681162C (en) 2007-03-15 2015-11-24 Novartis Ag Benzyl and pyridine derivatives as modulators of hedgehog pathway
JP2008280341A (ja) 2007-04-12 2008-11-20 Sumitomo Chemical Co Ltd ヒドラジド化合物およびその防除用途
US20090099195A1 (en) 2007-05-08 2009-04-16 Astrazeneca Ab Therapeutic Compounds 570
FR2929615B1 (fr) 2008-04-02 2010-12-17 Tfchem Composes c-aryl glycosides pour le traitement du diabete et de l'obesite.
MX353308B (es) 2008-05-21 2018-01-08 Ariad Pharma Inc Derivados fosforosos como inhibidores de cinasa.
CA2729045A1 (en) 2008-07-31 2010-02-04 Philippe Bergeron Pyrimidine compounds, compositions and methods of use
UA105185C2 (uk) 2008-08-27 2014-04-25 Такеда Фармасьютікал Компані Лімітед Піроли
MY159327A (en) 2009-02-27 2016-12-25 Ambit Biosciences Corp Jak kinase modulating quinazoline derivatives and methods of use thereof
US8461164B2 (en) 2009-08-31 2013-06-11 Dow Agrosciences, Llc. Pteridines and their use as agrochemicals
EA021113B1 (ru) 2009-09-03 2015-04-30 Бристол-Майерс Сквибб Кампани Хиназолины в качестве ингибиторов калиевых каналов
WO2012030918A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Adenosine a3 receptor modulating compounds and methods of use thereof
EP2611448A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation 7-cyclylquinazoline derivatives and methods of use thereof
WO2012030948A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Quinazoline compounds and methods of use thereof
WO2012028578A1 (de) 2010-09-03 2012-03-08 Bayer Cropscience Ag Substituierte anellierte pyrimidinone und dihydropyrimidinone
JP5947307B2 (ja) 2010-10-20 2016-07-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Ｋｃｎｑ２／３調節因子としての置換６−アミノ−ニコチンアミド
WO2012066122A1 (en) 2010-11-18 2012-05-24 Syngenta Participations Ag 2 - (pyridin- 2 -yl) -quinazoline derivatives and their use as microbicides
PY1153144A (es) 2010-12-10 2015-01-01 Gilead Sciences Inc Inhibidores macrocíclicos de virus flaviviridae
CN102584828B (zh) 2011-01-14 2016-01-27 上海艾力斯医药科技有限公司 吡咯烷[3，4-d]嘧啶衍生物、制备方法及其应用
US8791162B2 (en) 2011-02-14 2014-07-29 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
CN102911172A (zh) 2011-08-04 2013-02-06 上海恒瑞医药有限公司 杂芳基并嘧啶类衍生物、其制备方法和用途
JP6096778B2 (ja) 2011-09-01 2017-03-15 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ピロロピラジンキナーゼ阻害剤
CN103387490B (zh) 2012-05-09 2015-08-26 中国科学院兰州化学物理研究所 一种甲苯羰化合成苯乙酸的方法
PT2861604T (pt) 2012-06-08 2017-05-05 Gilead Sciences Inc Inibidores macrocíclicos de vírus flaviridae
CA2895129C (en) 2012-12-20 2022-07-05 Sanford-Burnham Medical Research Institute Quinazoline neurotensin receptor 1 agonists and uses thereof
CA2894642A1 (en) 2013-01-08 2014-07-17 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2014153666A1 (en) 2013-03-29 2014-10-02 Vida Therapeutics, Inc. Indoline compounds as granzyme b inhibitors
TWI527811B (zh) 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
SG11201600373YA (en) 2013-07-31 2016-02-26 Gilead Sciences Inc Syk inhibitors
WO2015155306A1 (en) 2014-04-11 2015-10-15 Almirall, S.A. New trpa1 antagonists
RU2017107558A (ru) 2014-09-15 2018-10-18 Руджен Холдингс (Кайман) Лимитед Производные пирролопиримидина в качестве антагонистов nmda-рецептора nr2b
ES2910226T3 (es) 2014-09-17 2022-05-12 Celgene Quanticel Res Inc Inhibidores de desmetilasa de histonas
WO2016049048A1 (en) 2014-09-22 2016-03-31 Rugen Holdings (Cayman) Limited Treatment of anxiety disorders and autism spectrum disorders
CN104803954B (zh) 2015-04-30 2018-01-26 上海应用技术学院 一种福沙那韦中间体的制备方法
PT3319939T (pt) 2015-07-08 2025-03-05 Cv6 Therapeutics Ni Ltd Inibidores de desoxiuridina-trifosfatase contendo hidantoína
WO2017069275A1 (ja) 2015-10-22 2017-04-27 田辺三菱製薬株式会社 新規二環性複素環化合物
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
WO2018112842A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
EP3558979B1 (en) * 2016-12-22 2021-02-17 Boehringer Ingelheim International GmbH Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
GB201700814D0 (en) 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
WO2018172250A1 (en) 2017-03-21 2018-09-27 Bayer Pharma Aktiengesellschaft 2-methyl-quinazolines
FR3066761B1 (fr) 2017-05-23 2020-10-30 Centre Nat Rech Scient Nouveaux composes inhibiteurs des canaux ioniques
HRP20230400T1 (hr) 2017-12-21 2023-06-23 Boehringer Ingelheim International Gmbh Benzilamino supstituirani piridopirimidinoni i derivati kao inhibitori sos1
US10676431B2 (en) 2018-03-05 2020-06-09 Bristol-Myers Squibb Company Phenylpyrrolidinone formyl peptide 2 receptor agonists
CN109776607B (zh) 2019-02-21 2021-06-04 青岛海洋生物医药研究院 芳基磷氧类和芳基磷硫类化合物及其制备方法和应用
MX2021010319A (es) 2019-03-01 2021-12-10 Revolution Medicines Inc Compuestos biciclicos de heteroarilo y usos de estos.
MX2021010323A (es) 2019-03-01 2021-12-10 Revolution Medicines Inc Compuestos bicíclicos de heterociclilo y usos de este.
CN115461342B (zh) 2020-05-09 2025-02-21 正大天晴药业集团股份有限公司 含磷的sos1抑制剂

Also Published As

Publication number Publication date
WO2022219035A1 (en) 2022-10-20
GEAP202316387A (en) 2023-12-25
JP2024513595A (ja) 2024-03-26
BR112023019030A2 (pt) 2023-10-24
CR20230485A (es) 2023-12-12
JOP20230252A1 (ar) 2023-10-12
CA3216503A1 (en) 2022-10-20
EP4322962A1 (en) 2024-02-21
AU2022258751A1 (en) 2023-10-05
DOP2023000218A (es) 2023-11-15
CO2023013469A2 (es) 2024-04-29
TW202304467A (zh) 2023-02-01
CL2023003045A1 (es) 2024-03-22
AR125672A1 (es) 2023-08-02
PH12023552869A1 (en) 2024-05-20
KR20230170032A (ko) 2023-12-18
US20240247015A1 (en) 2024-07-25
MX2023012187A (es) 2023-10-25
PE20240022A1 (es) 2024-01-04
CN117500507A (zh) 2024-02-02
IL307448A (en) 2023-12-01
EP4074317A1 (en) 2022-10-19

Similar Documents

Publication Publication Date Title
ECSP23077322A (es) Derivados de fósforo como nuevos inhibidores de sos1
DOP2018000226A (es) Nuevos derivados de pirazolopirimidina
CL2021001042A1 (es) Nuevos compuestos antihelmínticos
JOP20220131A1 (ar) مركبات أمينو كينولون تحمل بدائل تستخدم كمثبطات لـ dgkalpha من أجل تنشيط المناعة
DOP2019000206A (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
ECSP20008441A (es) Dihidrooxadiazinonas
UY37461A (es) 1,2,4 – triazolonas 2,4,5 trisustituida
DOP2020000023A (es) Nuevos derivados de quinolina
CU23366B7 (es) Oxazolidinonas substituidas para terapia de combinación
CO2020013876A2 (es) Nuevos derivados de quinolina
UY29803A1 (es) Derivados de adeninas, composiciones farmacéuticas conteniéndolos, procedimientos de preparación y aplicaciones
MX2022001803A (es) [1,2,4]triazolo[1,5-c]quinazolin-5-aminas.
DOP2019000275A (es) Nuevos derivados de pirazol bicíclicos
UY38816A (es) Nuevos derivados de isoquinolina
UY37971A (es) Derivados de indol macrocíclicos sustituidos
UY37973A (es) Derivados de indol macrocíclicos
UY37972A (es) Derivados de indol macrocíclicos sustituidos con cloro
CL2024000710A1 (es) Nuevos derivados de quinolina
DOP2024000096A (es) Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
CL2025002072A1 (es) Inhibidores de prmt5–mta.